Charles Schwab Investment Management Inc. Raises Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Charles Schwab Investment Management Inc. grew its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,028,924 shares of the company’s stock after acquiring an additional 129,749 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.09% of Teva Pharmaceutical Industries worth $22,677,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after buying an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its position in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after buying an additional 4,418,961 shares during the period. Lingotto Investment Management LLP lifted its position in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after buying an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after buying an additional 569,412 shares during the period. Finally, State Street Corp lifted its position in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after buying an additional 1,778,268 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.48 on Wednesday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The business has a 50 day moving average price of $18.09 and a two-hundred day moving average price of $18.26. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market cap of $18.68 billion, a PE ratio of -11.36, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on TEVA shares. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $23.43.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.